* autoimmune disease with biologics therapy * current treatment with tnf antibodies, convalescent plasma, bamlanivimab, or other experimental treatments for covid-19 * high-flow oxygen therapy, non-invasive / invasive ventilation (who-covid-19 progression scale \> 5) * pre-existing long-term ventilation or home oxygen therapy * child-pugh c liver cirrhosis * pregnancy or breastfeeding * patients with a life expectancy \< 90 days due to other medical conditions * limitation or discontinuation of therapy (e.g. refusal of artificial ventilation) * participation in another interventional study * previous participation in this study * interdependence between the patient and the coordinating investigator or other members of the study team

* autoimmune disease with biologics therapy * current treatment with tnf antibodies, convalescent plasma, bamlanivimab, or other experimental treatments for covid-19 * high-flow oxygen therapy, non-invasive / invasive ventilation (who-covid-19 progression scale \> 5) * pre-existing long-term ventilation or home oxygen therapy * child-pugh c liver cirrhosis * pregnancy or breastfeeding * patients with a life expectancy \< 90 days due to other medical conditions * limitation or discontinuation of therapy (e.g. refusal of artificial ventilation) * participation in another interventional study * previous participation in this study * interdependence between the patient and the coordinating investigator or other members of the study team

- autoimmune disease with biologics therapy - current treatment with tnf antibodies, convalescent plasma, bamlanivimab, or other experimental treatments for covid-19 - high-flow oxygen therapy, non-invasive / invasive ventilation (who-covid-19 progression scale > 5) - pre-existing long-term ventilation or home oxygen therapy - child-pugh c liver cirrhosis - pregnancy or breastfeeding - patients with a life expectancy < 90 days due to other medical conditions - limitation or discontinuation of therapy (e.g. refusal of artificial ventilation) - participation in another interventional study - previous participation in this study - interdependence between the patient and the coordinating investigator or other members of the study team

- autoimmune disease with biologics therapy - current treatment with tnf antibodies, convalescent plasma, bamlanivimab, or other experimental treatments for covid-19 - high-flow oxygen therapy, non-invasive / invasive ventilation (who-covid-19 progression scale > 5) - pre-existing long-term ventilation or home oxygen therapy - child-pugh c liver cirrhosis - pregnancy or breastfeeding - patients with a life expectancy < 90 days due to other medical conditions - limitation or discontinuation of therapy (e.g. refusal of artificial ventilation) - participation in another interventional study - previous participation in this study - interdependence between the patient and the coordinating investigator or other members of the study team